A decade after Bristol Myers Squibb first won approval for its PD-1 checkpoint inhibitor Opdivo, the cancer drug has been ...

BioNTech settles with NIH and UPenn over Comirnaty royalties, paying $750M to NIH and $400M to UPenn for 2020-2023, with ...

J&J partners with Kaken on STAT6 program, getting rights to KP-723 oral inhibitor. Kaken receives $30M upfront, potential $1.2B in milestone payments after Phase 1.

WuXi Apptec will sell its Advanced Technologies unit to the US private equity firm Altaris for an undisclosed amount, a ...

The Federal Trade Commission is praising an appeals court decision calling for Teva to delist five inhaler patents from the ...

The Centers for Medicare and Medicaid Services on Friday released detailed but heavily redacted explanations of how it ...

Applied Therapeutics CEO Shendelman exits; CFO Funtleyder becomes interim CEO after FDA rejects govorestat. Company withdraws ...

Bristol Myers Squibb's Sotyktu succeeds in Phase 3 psoriatic arthritis trials, as company leads TYK2 race against Takeda & ...

Eli Lilly dominates obesity market, megadeals decline, I&I sector thrives, and FDA's setback in misinformation fight.

The FDA on Friday issued two simultaneous cystic fibrosis approvals for Vertex Pharmaceuticals, but included boxed safety ...

Amgen, Eli Lilly and UCB sued the federal government, claiming that several STD clinics getting drug discounts under the ...

Sumitomo Pharma’s oral treatment for overactive bladder symptoms has won an expanded label from the FDA, and is now approved ...